ELITE PHARMACEUTICALS INC /NV/ Quarterly Common Stock, Shares, Outstanding from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Common Stock, Shares, Outstanding history and growth rate from Q1 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Common Stock, Shares, Outstanding for the quarter ending September 30, 2024 was 1.07B shares, a 5.36% increase year-over-year.
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 1.07B +54.4M +5.36% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 1.07B +54.4M +5.36% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 1.07B +54.4M +5.36% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 1.02B +3.87M +0.38% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 1.01B 0 0% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 1.01B +2.63M +0.26% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 1.01B +2.63M +0.26% Mar 31, 2023 10-K 2024-07-01
Q4 2022 1.01B +2.63M +0.26% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 1.01B +2.63M +0.26% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 1.01B 0 0% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 1.01B +2.11M +0.21% Mar 31, 2022 10-K 2023-06-29
Q4 2021 1.01B +2.11M +0.21% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 1.01B +2.11M +0.21% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 1.01B +170M +20.3% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 1.01B +169M +20.1% Mar 31, 2021 10-K 2022-06-29
Q4 2020 1.01B +175M +21% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 1.01B +176M +21.2% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 841M +12.1M +1.46% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 840M +15.6M +1.89% Mar 31, 2020 10-K 2021-06-14
Q4 2019 834M +13.5M +1.64% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 833M +16M +1.96% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 829M +24.3M +3.03% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 825M +22.3M +2.78% Mar 31, 2019 10-K 2020-06-30
Q4 2018 820M +31.7M +4.02% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 817M +30.9M +3.93% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 805M +23.9M +3.06% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 803M -125M -13.5% Mar 31, 2018 10-K 2019-06-21
Q4 2017 789M -122M -13.4% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 786M -108M -12% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 781M +49.8M +6.82% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 928M +216M +30.4% Mar 31, 2017 10-K 2018-06-14
Q4 2016 911M +224M +32.6% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 894M +213M +31.3% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 731M +71.9M +10.9% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 711M +80.4M +12.7% Mar 31, 2016 10-K 2017-06-14
Q4 2015 687M +78.3M +12.9% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 681M +89.1M +15.1% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 659M +91M +16% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 631M +70.9M +12.7% Mar 31, 2015 10-K 2016-06-15
Q4 2014 609M +95.7M +18.7% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 592M +96.9M +19.6% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 568M +172M +43.5% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 560M +186M +49.6% Mar 31, 2014 10-K 2015-06-15
Q4 2013 513M +163M +46.5% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 495M +145M +41.5% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 396M +49.5M +14.3% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 374M +42.7M +12.9% Mar 31, 2013 10-K 2014-06-30
Q4 2012 350M +85.5M +32.3% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 350M +94.9M +37.2% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 346M +103M +42.3% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 332M +151M +83.7% Mar 31, 2012 10-K 2013-06-21
Q4 2011 265M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 255M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 243M Jun 30, 2011 10-Q/A 2011-08-19
Q1 2011 181M Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.